Binu Kandathilparambil Sasi, PhD¹, Chiara Tarantelli, PhD^2*, Elisa Civanelli, MSc^2*, Eleonora Cannas, MSc^2*, Stacey M Fernandes, BS^1*, Samantha J. Shupe, BS^1*, Michael Lahn^3*, Lars van der Veen^4*, Giusy Di Conza, PhD^3*, Francesco Bertoni, MD² and Jennifer R. Brown, MD, PhD⁵

¹Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
²Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland
³iOnctura SA, Geneva, Switzerland
⁴iOnctura BV, Amsterdam, Netherlands
⁵Chronic Lymphocytic Leukemia Center, Division of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

Dhananjaya Pal, PhD^1*, Page Mangum Arditti, B.S.^1*, Krishnaiah Maddeboina, PhD^1,2*, Cody C. McHale, PhD^1*, Hsih-Te Yang^3*, Bharath Yada, PhD^1*, Hailey Lynn Dryden, M.S.^1*, David M Foureau, PhD^4,5 and Donald L. Durden, MD, PhD^1,2*

¹Molecular Targeted Therapeutics Laboratory, Atrium Health Levine Cancer Institute, Charlotte, NC
²Department of Biochemistry, AHWFB Comprehensive Cancer Center, Wake Forest University School of Medicine, Winston-Salem, NC
³Department of Biostatistics and Data Sciences, Atrium Health Levine Cancer Institute, Charlotte, NC
⁴Immune Monitoring Core Laboratory, Atrium Health Levine Cancer Institute, Charlotte, NC
⁵Hematology and Oncology, Wake Forest University School of Medicine, Winston-Salem, NC

Nuria Profitos-Peleja, PhD^1*, Marcelo Lima Ribeiro, PhD^2*, Jeronimo Parra, MSc^3*, Miranda Fernandez-Serrano, MSc^3,4*, Pau Marin-Escudero, MSc^3*, Joan Josep Bech, PhD^5*, Carolina De La Torre, PhD^6*, Adar Makovski Silverstein, PhD^7*, Steve Cosenza, PhD^7*, Steven M. Fruchtman, MD⁷, Manel Esteller, MD^8,9,10,11 and Gael Roue, PhD¹²

¹Lymphoma Translational group, Josep Carreras Leukaemia Research Institute, Badalona, ESP
²Lymphoma Translational group, Josep Carreras Leukemia Research Institute (IJC), Badalona, ESP
³Lymphoma Tranlastional group, Josep Carreras Leukaemia Research Institute, Badalona, Spain
⁴Department of Biochemistry and Molecular Biology, Autonomous University of Barcelona (UAB), Barcelona, Spain
⁵Proteomics Units, Josep Carreras Leukaemia Research Institute, Badalona, Spain
⁶Proteomics Unit, Josep Carreras Leukaemia Research Institute (IJC), Badalona, ESP
⁷Onconova Therapeutics, Newton, PA
⁸Josep Carreras Leukaemia Research Institute, Badalona, Spain
⁹School of Medicine, Physiological Sciences Department, University of Barcelona, Badalona, Spain
¹⁰Centro de Investigacion Biomedica en Red Cancer, Madrid, Spain
¹¹Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain
¹²Lymphoma translational group, Josep Carreras Leukemia Research Institute, Badalona, Spain

Keito Suto^1*, Masahiro Chiba^2*, Takashi Ishio^2*, Hideki Goto, MD, PhD^2*, Tomoyuki Endo², Michiyuki Maeda^3*, Takanori Teshima, M.D., Ph.D.² and Masao Nakagawa, MD, PhD²

¹Department of Hematology, Hokkaido University Faculty of Medicine, Kushiro-Shi Nakazono-Cho, HOK, Japan
²Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Japan
³Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto, Japan

Nurulhuda Mustafa, PhD^1,2*, Zubaida Talal Alnaseri, MSc^1*, Darrel Egk Jian Tan, BSc^1*, Irfan Azaman, BSc^1*, David Thanh Truong Quach, PhD^3*, Wan Hsin Lim, PhD^3* and Wee-Joo Chng, MBBS, PhD, FRCPath, FRCP^1,4,5

¹Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore
²Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
³Experimental Drug Development Centre, A*STAR, Singapore, Singapore
⁴Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore
⁵Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

Manuel Pazos II, MS, BS^1*, Brian Estrella, PhD^1*, Ted B. Piorczynski, PhD^2*, Seda S. Tolu, MD³, Wenxuan Huang^1*, Yun Kyoung Ryu, MD, PhD¹ and Jennifer E Amengual, MD^4*

¹Division of Hematology and Oncology, Columbia University Irving Medical Center, New York
²Division of Hematology and Oncology, Columbia University Irving Medical Center, New York, NY
³Division of Hematology and Oncology, Columbia University Irving Medical Center, New York City, NY
⁴Lymphoma Program, Division of Hematology and Oncology, Columbia University Irving Medical Center, New York

Jelena Urosevic, PhD^1*, James T. Lynch^1*, Stefanie Meyer^2*, Nevin Yusufova^2*, Elizabeth Wiseman^1*, Paul Waring^1*, Ted Hong^3*, Zuleyha Ozen^3*, Haiyun Wang^3*, Lauren Bradshaw^1*, Hannah Tomczak^2*, Ho Man Chan^3*, Ruben Reyes^2*, Susan Critchlow^1*, Anas Younes² and Emma Dean^1*

¹Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom
²Haematology R&D, AstraZeneca, Waltham
³Research and Early Development, Oncology R&D, AstraZeneca, Waltham

Torsten Steinbrunn, MD, PhD^1,2,3,4*, Ryosuke Shirasaki, MD^1,3,4,5,6*, Olga Dashevsky, PhD^1,3,4,6*, Huihui Tang, PhD^1,3,4*, Shizuka Yamano, PhD^1,3*, Rin Mizuno, MD, PhD^3,4,7*, Takeru Sugihara, MD^1,3,4*, Phaik Ju Teoh^1,3,4,8,9*, Lisa B Leypoldt, MD^1,3,4,10*, Mariko Kaji, MD^1*, Jeffrey Sorrell, BA^1*, Brian J Glassner, PhD^1,3,4*, Ricardo De Matos Simoes, PhD^1,3,4,6*, James Christensen, PhD^11* and Constantine S Mitsiades, MD^1,3,4,6

¹Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
²Department of Medicine II, University Hospital of Wuerzburg, Wuerzburg, Germany
³Department of Medicine, Harvard Medical School, Boston, MA
⁴Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA
⁵Department of Medical Oncology, Teikyo University Hospital, Tokyo, Japan
⁶Ludwig Center, Harvard Medical School, Boston, MA
⁷Dana-Farber Cancer Institute, Boston, MA
⁸Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
⁹Cancer Science Institute of Singapore, Singapore, Singapore
¹⁰Department of Hematology, Oncology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
¹¹Mirati Therapeutics, San Diego, CA

Yigen Li, PhD^1*, Amy Barber^1*, Shannon Martin, MSc^1*, Salomon Morales, MSc^1*, Sarah Bird, BMBCh^1*, Yakinthi Chrisochoidou, PhD^1* and Charlotte Pawlyn, MBBChir, PhD^1,2

¹The Institute of Cancer Research, London, United Kingdom
²The Royal Marsden NHS Foundation Trust, London, United Kingdom

Qi Han^1*, Yan Gu^1*, Chan Yang^1*, Jun Li^1*, Sinisa Dovat, MD, PhD², Chunhua Song, MD, PhD³ and Zheng Ge, MD, PhD¹

¹Department of Hematology, Zhongda Hospital, School of Medicine, Southeast University, Institute of Hematology Southeast University, Nanjing, China
²Hershey Medical Center, Pennsylvania State University Medical College, Hershey, PA
³Division of Hematology, The Ohio State University Wexner Medical Center and The James Cancer Hospital, Columbus, OH

Gawin R. Stoll, MSc^*, Dorette Van Ingen Schenau^*, Willem P. J. Cox, MSc^*, Ziqin Tang^*, Emmely M. Wagener^*, Laurens T. van der Meer, PhD^* and Frank N. van Leeuwen, PhD

Princess Maxima Center for Pediatric Oncology, Utrecht, Netherlands

Carina Lynn Gehlert^1*, Denis Martin Schewe^2,3*, Katja Klausz^1,2*, Steffen Krohn^1*, Dorothee Winterberg^1*, Fotini Vogiatzi^4*, Ammelie Svea Boje^1*, Anja Lux^5*, Falk Nimmerjahn^5*, Regina Scherließ^6*, Andreas Humpe^7*, Martin Schrappe, MD^2,4, Gunnar Cario, MD^2,8*, Thomas Valerius^2,9*, Lars Fransecky^2,10*, Monika Brüggemann^2,10*, Claudia D Baldus, MD^2,10*, Martin Gramatzki¹, Lennart Lenk^2,4*, Christian Kellner, PhD^7* and Matthias Peipp^1,2*

¹Division of Antibody-Based Immunotherapy, Department of Hematology and Oncology, Kiel University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
²Clinical Research Unit CATCH ALL (KFO 5010/1) funded by the Deutsche Forschungsgemeinschaft, Kiel, Germany
³Department of Pediatrics, Otto-von-Guericke University Magdeburg, Magdeburg, Germany
⁴Department of Pediatrics I, University Hospital Schleswig-Holstein, Kiel, Germany
⁵Division of Genetics, Department of Biology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
⁶Department of Pharmaceutics and Biopharmaceutics, Kiel University, Kiel, Germany
⁷Division of Transfusion Medicine, Cell Therapeutics and Haemostaseology, University Hospital, LMU Munich, Munich, Germany
⁸Department of Pediatrics I, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
⁹Division of Stem Cell Transplantation and Immunotherapy, Department of Hematology and Oncology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
¹⁰University Hospital Schleswig-Holstein, Department of Hematology and Oncology, Campus Kiel, Kiel, Germany

Kristopher A Knight, BS¹, Harrison C. Brown, PhD^2*, Kinnede R. White^3*, H. Trent Spencer, PhD^3*, Christopher B Doering, PhD³ and Sunil S. Raikar, MD³

¹Molecular and Systems Pharmacology, Emory University, Atlanta, GA
²Expression Therapeutics, Tucker, GA
³Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Emory University and Children's Healthcare of Atlanta, Atlanta, GA

Vishakha Anand Pawar, PhD¹, Akanksha Aradhya^2*, Daniel Galvan^2*, Gautam Borthakur, MD³, Swami P. Iyer, MD⁴, Mark Kirschbaum^5*, David Blake, PhD^6*, Tapan M. Kadia, MD³, Deepa Sampath, PhD¹ and Francisco Vega, MD, PhD⁷

¹Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX
²Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
³Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
⁴Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
⁵Cyclacel Pharmaceuticals, Berkeley Heights
⁶Cyclacel Limited, Dundee, GBR
⁷Department of Hematopathology, MD Anderson Cancer Center , Houston, TX

Nicolas Chatain, PhD^1,2*, Julian Baumeister^1,2*, Marcelo Szymanski de Toledo^1,2*, Dickson W.L. Wong^2,3*, Siddharth Gupta^1,2*, Kristina Pannen^1,2*, Bärbel Junge^1,2*, Tim H. Brümmendorf^1,2, Peter Boor^2,3* and Steffen Koschmieder^1,2

¹Department of Medicine (Hematology, Oncology, Hemostaseology, and SCT), RWTH Aachen University, Faculty of Medicine, Aachen, Germany
²Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Aachen, Germany
³Institute of Pathology, RWTH Aachen University, Faculty of Medicine, Aachen, Germany

Katie Moosic^1,2, Kristine Olson^1*, David J Feith, BS, PhD^1* and Thomas P. Loughran Jr., MD¹

¹UVA Comprehensive Cancer Center, Charlottesville, VA
²Department of Pathology, Charlottesville

Daisy Diaz Rohena, BS¹, Arnau Peris Cuesta^1*, Bailey Slawin^1*, Janani Ravikrishnan, PhD^2*, Chaomei Liu^1*, Charmelle Williams, MSc, BSc^1*, Wanyi Hu^3*, Peiyi Zhang^3*, Philip Thompson, MBBS⁴, William G. Wierda, MD, PhD⁴, Nitin Jain, MD⁴, Sachet Shukla, PhD^5*, Guangrong Zheng^3*, Daohong Zhou, MD^6*, Jennifer A. Woyach, MD² and Deepa Sampath, PhD¹

¹Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX
²The Ohio State University Comprehensive Cancer Center, Columbus, OH
³Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL
⁴Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
⁵Department of Hematopoietic Biology & Malignancy, The University of Texas M.D. Anderson Cancer Center, Houston
⁶Department of Biochemistry and Structural Biology and Center for Innovative Drug Discovery, University of Texas Health Science Center at San Antonio, San Antonio, TX

Layla M. Saleh^1*, Maissa Mhibik, PhD^1*, Jonathan Chen^1*, Clare Sun, MD², Christopher Pleyer, MD^3* and Adrian Wiestner, MD⁴

¹Laboratory of Lymphoid Malignancies, Hematology Branch, NHLBI, Bethesda, MD
²National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
³Laboratory of Lymphoid Malignancies, Hematology Branch, NHLBI, bethesda, MD
⁴Hematology Branch, National Heart, Lung, and Blood Institute, NIH, NHLBI, Bethesda, MD

Andrea Aroldi, MD^1*, Mario Mauri, PhD^2*, Daniele Ramazzotti, PhD^3*, Simone Piane, MD^3*, Matteo Villa, MS^2*, Federica Malighetti, MS^2*, Chiara Borella, MD^4*, Elisa Bossi, MD^5*, Federica Cocito, MD^6*, Carolina Steidl, MD^7*, Luca Mologni, PhD^8*, Rocco Piazza, MD, PhD^3,9* and Carlo Gambacorti-Passerini, MD^6,8

¹Hematology Division and Bone Marrow Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, MB, Italy
²Department of Medicine and Surgery, University of Milano-Bicocca, Monza, ITA
³Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy
⁴Department of Hematology, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
⁵Department of Hematology, Fondazione IRCCS San Gerardo dei Tintori, Monza, ITA
⁶Hematology Department, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
⁷Lymphoma Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
⁸Department of Medicine and Surgery, University Milano-Bicocca, Monza, Italy
⁹Hematology Division and Bone Marrow Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy